Cosmetic Evaluation of a Biomimetic Lamellar Serum Containing Oleyl Adapalenate for Acne-Prone Skin: An Exploratory Pilot Study
Adapalene is a well-established topical acne treatment, but its use may be limited by irritation, particularly in sensitive skin. Oleyl adapalenate (OA), a lipid-conjugated adapalene derivative, has demonstrated cosmetic efficacy in photoaged skin; however, clinical evidence in acne-prone skin remains limited. This study evaluated the clinical performance and tolerability of a biomimetic lamellar serum containing OA, supported by analytical characterization. The finished formulation exhibited antibacterial activity against Cutibacterium acnes (ATCC 6919), achieving a ≥5.2-log reduction in viability. LC-MS/MS detected OA in the finished formulation, and 1H-NMR analysis showed signals consistent with an oleyl adapalenate-type structure. A 4-week, single-arm, open-label pilot study was conducted in 20 participants with mild-to-moderate acne-prone skin. The serum was applied twice daily throughout the study period. After four weeks, favorable within-subject changes were observed in acne-related and skin barrier-associated measures using Holm–Bonferroni-adjusted statistical significance reported for the specified parameters, including non-inflammatory lesion counts (19.3%), inflammatory lesions (57.2%), Acne Severity Index (ASI) (31.6%), sebum-covered area (87.1%), Investigator’s Global Assessment (IGA) scores (36.7%), and trans-epidermal water loss (TEWL) (11.2%), along with increased stratum corneum hydration (13.6%). No irritation was observed in either the 24 h primary irritation patch test or during the 4-week clinical evaluation, suggesting favorable tolerability of the OA-containing formulation. These findings suggest that the OA-containing formulation may improve acne-related skin parameters and skin barrier-associated measures while demonstrating favorable skin tolerability without observable irritation. However, because the study was exploratory and lacked vehicle- and ingredient-specific controls, further randomized, blinded, controlled studies are required to confirm these findings.
Authors
- Gaewon Nam (ORCID: https://orcid.org/0000-0002-4623-588X)
- Changmin Sung (ORCID: https://orcid.org/0000-0001-7318-7353)
- Sekyoo Jeong (ORCID: https://orcid.org/0000-0002-9201-0227)
- Yeojeong Cho
- Byeong Deog Park (ORCID: https://orcid.org/0000-0001-5899-6558)
- Yerim Kim (ORCID: https://orcid.org/0009-0009-8406-7678)
Institutions
- Yonsei University (KR)
- Komipharm International (South Korea) (KR)
- Korea Institute of Science and Technology (KR)
Publication Details
- Journal
- Cosmetics
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/cosmetics13060318
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00